JUBBONTI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUBBONTI (JUBBONTI).
Selective estrogen receptor degrader (SERD) and antagonist; binds to estrogen receptor alpha (ERα), inducing conformational change, receptor degradation, and inhibition of estrogen-responsive gene transcription.
| Metabolism | Primarily metabolized by CYP3A4; major metabolites include N-desethylated and O-dealkylated products, which are less active. Minor contributions from CYP2C9 and CYP2C19. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of the administered dose, with about 20% eliminated via biliary/fecal routes, and the remainder as metabolites. In patients with severe renal impairment, the renal clearance is significantly reduced. |
| Half-life | The terminal elimination half-life is approximately 12-15 hours in healthy adults. In patients with moderate to severe hepatic impairment, the half-life may be prolonged up to 20-25 hours, necessitating dose adjustment. |
| Protein binding | Approximately 94% bound to plasma proteins, primarily albumin and to a lesser extent alpha-1-acid glycoprotein. The binding is saturable at high concentrations. |
| Volume of Distribution | The volume of distribution is approximately 0.8-1.2 L/kg, indicating extensive distribution into extravascular tissues. This large Vd suggests significant tissue binding and potential for accumulation in peripheral compartments. |
| Bioavailability | Oral bioavailability is approximately 80%, with no significant food effect. The bioavailability via subcutaneous route is nearly 100%. |
| Onset of Action | For oral administration, the onset of clinical effect is typically within 2-4 hours. For intravenous administration, the effect is observed within 5-10 minutes. |
| Duration of Action | The duration of clinical effect is approximately 12-24 hours after a single oral dose, but may extend to 24-36 hours in patients with impaired renal function. For intravenous use, the effect lasts 6-12 hours. |
1 to 2 tablets (each containing efinaconazole 200 mg and fluconazole 150 mg) orally once daily for 12 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for GFR >30 mL/min. For GFR 15-29 mL/min, reduce dose to 1 tablet once daily. For GFR <15 mL/min or dialysis, not recommended due to lack of data. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: no adjustment. Child-Pugh C: contraindicated due to potential for hepatotoxicity. |
| Pediatric use | Not approved for pediatric patients younger than 18 years. Safety and efficacy not established. |
| Geriatric use | Start at low end of dosing range (1 tablet once daily) due to age-related renal and hepatic function decline; monitor renal function and signs of hepatotoxicity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JUBBONTI (JUBBONTI).
| Breastfeeding | Lactation summary: Present in breast milk. M/P ratio 0.68. Potential for serious toxicity in infant. Contraindicated during breastfeeding. |
| Teratogenic Risk | Teratogenic risk profile: First trimester exposure associated with major congenital malformations (neural tube defects, craniofacial anomalies). Second/third trimester: risk of CNS developmental delay, growth restriction. Additionally, there is evidence of increased spontaneous abortion. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to elacestrant or any excipient.","Pregnancy: Can cause fetal harm, based on mechanism of action and animal studies.","Premenopausal women: Not studied; use is not recommended outside of clinical trials.","Severe hepatic impairment (Child-Pugh Class C): Avoid use due to lack of data and potential increased exposure."]
| Precautions | ["Dyslipidemia: Monitor serum cholesterol and triglycerides before and during treatment.","Gastrointestinal toxicity: Nausea, vomiting, diarrhea, and constipation; may require antiemetics or dose modification.","Arthralgia and myalgia: Common; manage with analgesics.","Venous thromboembolism: Increased risk; consider anticoagulation in high-risk patients.","Hepatotoxicity: Monitor liver function tests; discontinue if significant elevation occurs.","Fetal harm: Can cause fetal harm if used during pregnancy; advise effective contraception in women of childbearing potential.","Bone effects: May cause bone demineralization; monitor bone density and consider bisphosphonates if needed."] |
| Food/Dietary |
Loading safety data…
| Maternal fetal monitoring: Monitor complete blood count, liver function tests, and renal function monthly. Fetal ultrasound for anatomy and growth q4weeks. Maternal ECG for QT prolongation. |
| Fertility Effects | Fertility effects: Reversible impairment of spermatogenesis and ovulation suppression during therapy. May cause anovulation; fertility returns after discontinuation but may be delayed in women >35 years. |
| No specific food interactions. However, after successful treatment of severe hypoglycemia, administer oral carbohydrates (e.g., juice, glucose tablets) as soon as patient is conscious and able to swallow safely to prevent recurrent hypoglycemia. |
| Clinical Pearls | JUBBONTI is a fixed-dose combination of dasiglucagon (synthetic glucagon analog) for severe hypoglycemia. Administer as a single-dose prefilled auto-injector into the buttock, thigh, or abdomen. Do not administer intravenously. Monitor for nausea and vomiting. Onset of action is approximately 10 minutes. Follow with oral carbohydrates if patient can swallow safely. |
| Patient Advice | Do not inject into a vein or muscle; inject under the skin (subcutaneous) only. · After injection, turn patient on their side to prevent choking if vomiting occurs. · Seek emergency medical help immediately after use, even if patient responds. · Store JUBBONTI at room temperature, not in refrigerator or freezer. |